Disease · MONDO_0018097
infantile spasms
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. infantile spasms. Diseases, record MONDO_0018097. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0018097
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- IESS, Intellectual disability - hypsarrhythmia, West syndrome, West's syndrome, infantile epileptic spasms syndrome, infantile spasms syndrome, intellectual disability-hypsarrhythmia syndrome
- Open Targets
- Highest stage of its drugs
- Approval, for 3 of its 18 drugs, from DailyMed, EMA Human Drugs, FDA, PMDA and TTD
- Open Targets
Drugs18
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| VIGABATRIN | CHEMBL89598 | Small molecule | Approval | DailyMed, EMA Human Drugs, PMDA and TTD | 13 | 8 | 8 | Drugs and targets |
| CORTICOTROPIN | CHEMBL1201610 | Approval | DailyMed | 4 | 3 | 3 | Drugs and targets | |
| GANAXOLONE | CHEMBL1568698 | Small molecule | Approval | EMA Human Drugs and FDA | 4 | 2 | 2 | Drugs and targets |
| PREDNISOLONE | CHEMBL131 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| CANNABIDIOL | CHEMBL190461 | Small molecule | Phase 3 | ClinicalTrials.gov and TTD | 5 | 4 | 4 | Drugs and targets |
| PYRIDOXINE | CHEMBL1364 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| COSYNTROPIN | CHEMBL2103784 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| METHYLPREDNISOLONE | CHEMBL650 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CARBAMAZEPINE | CHEMBL108 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FENFLURAMINE | CHEMBL87493 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 18
See all 18 drugsTargets36
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| MC2R | Adrenocorticotropic hormone receptor | 2 | Melanocortin receptor 2 agonist | Approval | https://conductscience.org/library/genes/4158 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 2 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| ABAT | 4-aminobutyrate aminotransferase, mitochondrial | 1 | Gamma-amino-N-butyrate transaminase inhibitor | Approval | https://conductscience.org/library/genes/18 | Drugs and targets |
| ALDH5A1 | Succinate-semialdehyde dehydrogenase, mitochondrial | 1 | Succinate semialdehyde dehydrogenase inhibitor | Phase 2 | https://conductscience.org/library/genes/7915 | Drugs and targets |
| CNR1 | Cannabinoid receptor 1 | 1 | Cannabinoid CB1 receptor negative allosteric modulator | Phase 3 | https://conductscience.org/library/genes/1268 | Drugs and targets |
| GABRA1 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive allosteric modulator | Approval | https://conductscience.org/library/genes/2554 | Drugs and targets |
| GABRA2 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive allosteric modulator | Approval | https://conductscience.org/library/genes/2555 | Drugs and targets |
| GABRA3 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive allosteric modulator | Approval | https://conductscience.org/library/genes/2556 | Drugs and targets |
| GABRA4 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive allosteric modulator | Approval | https://conductscience.org/library/genes/2557 | Drugs and targets |
| GABRA5 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive allosteric modulator | Approval | https://conductscience.org/library/genes/2558 | Drugs and targets |
1 to 10 of 36
See all 36 targetsTrials23
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00441896 | A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms | Phase 2 | 57 | 2023-06-02 | Infantile Spasms | GANAXOLONE | Its record names the disease | ClinicalTrials.gov |
| NCT00442104 | Open-label Extension to Protocol 1042-0500 | Phase 2 | 54 | 2023-06-02 | Infantile Spasms | GANAXOLONE | Its record names the disease | ClinicalTrials.gov |
| NCT03976076 | A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients | Phase 2 | 16 | 2023-02-16 | Refractory Infantile Spasms | JBPOS-0101 | Its record names the disease | ClinicalTrials.gov |
| NCT02551731 | Cannabidiol Oral Solution for Treatment of Refractory Infantile Spasms | Phase 2 | 9 | 2018-09-19 | Spasms, Infantile | CANNABIDIOL | Its record names the disease | ClinicalTrials.gov |
| NCT02953548 | Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7) | Phase 3 | 9 | 2020-07-23 | Infantile Spasms | CANNABIDIOL | Its record names the disease | ClinicalTrials.gov |
| NCT02954887 | Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7) | Phase 3 | 9 | 2020-07-23 | Infantile Spasms | CANNABIDIOL | Its record names the disease | ClinicalTrials.gov |
| NCT03421496 | A Study to Assess Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms | Phase 3 | 2 | 2023-06-07 | Infantile Spasm | CANNABIDIOL, VIGABATRIN | Its record names the disease | ClinicalTrials.gov |
| NCT01073579 | Sabril Patient Registry | 9,423 | Infantile Spasms, Refractory Complex Partial Seizures in Adults | VIGABATRIN | Its record names the disease | ClinicalTrials.gov | ||
| NCT03347526 | A Novel Approach to Infantile Spasms | Phase 3 | 394 | Infantile Spasm | COSYNTROPIN, VIGABATRIN | Its record names the disease | ClinicalTrials.gov | |
| NCT04302116 | Vigabatrin With High Dose Prednisolone Combination Therapy vs Vigabatrin Alone for Infantile Spasm | Not applicable | 250 | Infantile Spasm, West Syndrome | PREDNISOLONE, VIGABATRIN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 23
See all 23 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials30
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0018097
GET https://conductscience.org/api/diseases/v1/MONDO_0018097/targets?page=2